patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_788525 | REC_0005301 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 32 | 13.7 | 54 | female | 0 | 9 | 6 | 3 | entrectinib 600 mg daily | 6.2 | true | MSS | 2026-03-15T05:35:58.157333+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_405143 | REC_0005302 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 16 | 16.2 | 68 | female | 1 | 21 | 8.7 | 6 | osimertinib 80 mg daily | 12.2 | true | MSI-H | 2026-03-15T05:35:58.157562+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_219358 | REC_0005303 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 27 | 11.1 | 66 | female | 1 | 24 | 7.5 | 4 | sotorasib 960 mg daily | 15.2 | true | MSS | 2026-03-15T05:35:58.157795+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_358312 | REC_0005304 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 25 | 10.2 | 78 | female | 1 | 9 | 5.3 | 2 | alectinib 600 mg BID | 11.6 | false | MSS | 2026-03-15T05:35:58.158027+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_681544 | REC_0005305 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 24 | 14.6 | 61 | male | 1 | 16 | 4.1 | 2 | alectinib 600 mg BID | 21.9 | true | MSI-H | 2026-03-15T05:35:58.158306+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_807310 | REC_0005306 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 32 | 12.4 | 67 | male | 1 | 11 | 6 | 4 | pembrolizumab 200 mg q3w | 16.4 | false | MSS | 2026-03-15T05:35:58.158546+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_353423 | REC_0005307 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 16 | 20.5 | 62 | female | 1 | 16 | 4.2 | 0 | entrectinib 600 mg daily | 15.9 | false | MSI-H | 2026-03-15T05:35:58.158782+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_430918 | REC_0005308 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 24 | 7.5 | 81 | female | 2 | 16 | 4.6 | 8 | pembrolizumab 200 mg q3w | 10.6 | true | MSS | 2026-03-15T05:35:58.159011+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_585520 | REC_0005309 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 9.6 | 67 | female | 1 | 21 | 4.9 | 8 | osimertinib 80 mg daily | 15.6 | true | MSS | 2026-03-15T05:35:58.159240+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_696344 | REC_0005310 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 19 | 3.6 | 70 | female | 1 | 49 | 4.9 | 2 | pembrolizumab 200 mg q3w | 14 | false | MSS | 2026-03-15T05:35:58.159469+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_327510 | REC_0005311 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 28 | 8.9 | 64 | female | 1 | 29 | 4.2 | 3 | pembrolizumab 200 mg q3w | 10.8 | true | MSS | 2026-03-15T05:35:58.159702+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_960466 | REC_0005312 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 33 | 16.4 | 79 | female | 0 | 18 | 6.2 | 7 | osimertinib 80 mg daily | 8.7 | true | MSI-H | 2026-03-15T05:35:58.159933+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_546511 | REC_0005313 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 27 | 5.7 | 74 | female | 0 | 30 | 4.7 | 2 | carboplatin + paclitaxel + pembrolizumab | 8.4 | false | MSS | 2026-03-15T05:35:58.160209+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_947877 | REC_0005314 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 22 | 17.2 | 67 | female | 0 | 12 | 6.6 | 1 | sotorasib 960 mg daily | 33.4 | true | MSS | 2026-03-15T05:35:58.160458+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_866110 | REC_0005315 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 3.8 | 67 | male | 1 | 28 | 6.7 | 3 | carboplatin + paclitaxel + pembrolizumab | 12.1 | false | MSS | 2026-03-15T05:35:58.160694+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_227867 | REC_0005316 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 21 | 7.1 | 63 | female | 0 | 17 | 6 | 0 | osimertinib 80 mg daily | 29.9 | false | MSS | 2026-03-15T05:35:58.160926+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_297510 | REC_0005317 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 34 | 10.1 | 78 | female | 1 | 22 | 4.9 | 5 | osimertinib 80 mg daily | 18.2 | true | MSS | 2026-03-15T05:35:58.161156+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_742792 | REC_0005318 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 30 | 5 | 64 | male | 1 | 13 | 7.9 | 6 | entrectinib 600 mg daily | 6.8 | false | MSS | 2026-03-15T05:35:58.161450+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_296875 | REC_0005319 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 25 | 15.9 | 80 | female | 2 | 17 | 5 | 8 | pembrolizumab 200 mg q3w | 12.4 | false | MSS | 2026-03-15T05:35:58.161691+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_343644 | REC_0005320 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 24 | 18.2 | 81 | female | 2 | 16 | 6.4 | 1 | alectinib 600 mg BID | 18.2 | true | MSI-H | 2026-03-15T05:35:58.161922+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_989928 | REC_0005321 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 30 | 10.6 | 59 | female | 0 | 16 | 6.8 | 0 | osimertinib 80 mg daily | 26.8 | true | MSI-H | 2026-03-15T05:35:58.162160+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_194163 | REC_0005322 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 33 | 10.8 | 69 | female | 0 | 16 | 5.6 | 4 | osimertinib 80 mg daily | 13.1 | true | MSI-H | 2026-03-15T05:35:58.162394+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_918792 | REC_0005323 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 27 | 6.9 | 66 | female | 0 | 37 | 3.2 | 2 | carboplatin + paclitaxel + pembrolizumab | 5.8 | false | MSS | 2026-03-15T05:35:58.162622+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_266986 | REC_0005324 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 15.6 | 68 | female | 0 | 10 | 2 | 6 | alectinib 600 mg BID | 11.9 | false | MSI-H | 2026-03-15T05:35:58.162853+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_855078 | REC_0005325 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 6.4 | 81 | female | 1 | 9 | 8 | 4 | carboplatin + paclitaxel + pembrolizumab | 11.3 | false | MSS | 2026-03-15T05:35:58.163080+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_961214 | REC_0005326 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 22 | 7.5 | 75 | male | 3 | 9 | 7 | 5 | pembrolizumab 200 mg q3w | 15.5 | true | MSS | 2026-03-15T05:35:58.163311+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_379980 | REC_0005327 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 9.6 | 51 | female | 0 | 34 | 6.4 | 4 | carboplatin + paclitaxel + pembrolizumab | 17.3 | false | MSS | 2026-03-15T05:35:58.163544+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_121294 | REC_0005328 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 5.6 | 55 | female | 0 | 49 | 6.9 | 6 | carboplatin + paclitaxel + pembrolizumab | 7.3 | true | MSS | 2026-03-15T05:35:58.163775+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_493528 | REC_0005329 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 17 | 11.5 | 79 | female | 2 | 15 | 3.7 | 2 | osimertinib 80 mg daily | 5.6 | true | MSS | 2026-03-15T05:35:58.164006+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_243922 | REC_0005330 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 22 | 3.8 | 78 | female | 1 | 40 | 7.5 | 7 | pembrolizumab 200 mg q3w | 11.4 | true | MSS | 2026-03-15T05:35:58.164281+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_346429 | REC_0005331 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 34 | 6.2 | 76 | female | 1 | 36 | 5.5 | 9 | carboplatin + paclitaxel + pembrolizumab | 12.6 | false | MSS | 2026-03-15T05:35:58.164567+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_405370 | REC_0005332 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 17 | 12.2 | 74 | female | 1 | 16 | 5.9 | 5 | sotorasib 960 mg daily | 10.4 | false | MSI-H | 2026-03-15T05:35:58.164806+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_482154 | REC_0005333 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 24 | 6.1 | 54 | male | 0 | 64 | 5.8 | 1 | carboplatin + paclitaxel + pembrolizumab | 14.7 | false | MSS | 2026-03-15T05:35:58.165039+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_974612 | REC_0005334 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 6 | 59 | female | 0 | 54 | 5 | 5 | carboplatin + paclitaxel + pembrolizumab | 13.3 | true | MSS | 2026-03-15T05:35:58.165273+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_928666 | REC_0005335 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 31 | 11 | 77 | female | 2 | 23 | 5.6 | 3 | sotorasib 960 mg daily | 4 | false | MSS | 2026-03-15T05:35:58.165505+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_975005 | REC_0005336 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 29 | 11.9 | 62 | female | 0 | 28 | 5.4 | 6 | osimertinib 80 mg daily | 13.3 | false | MSS | 2026-03-15T05:35:58.165738+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_992345 | REC_0005337 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 17.9 | 67 | female | 1 | 22 | 5 | 5 | osimertinib 80 mg daily | 11.3 | false | MSS | 2026-03-15T05:35:58.165968+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_338660 | REC_0005338 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 10.5 | 76 | male | 2 | 13 | 6 | 5 | osimertinib 80 mg daily | 13.7 | false | MSI-H | 2026-03-15T05:35:58.166202+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_976976 | REC_0005339 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 13.3 | 74 | female | 1 | 17 | 5.5 | 7 | alectinib 600 mg BID | 13.7 | true | MSI-H | 2026-03-15T05:35:58.166437+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_344459 | REC_0005340 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 14 | 13.1 | 60 | female | 0 | 22 | 4.1 | 4 | pembrolizumab 200 mg q3w | 4 | true | MSS | 2026-03-15T05:35:58.166671+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_947688 | REC_0005341 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 33 | 6.5 | 68 | male | 1 | 51 | 5.4 | 5 | carboplatin + paclitaxel + pembrolizumab | 8.3 | false | MSS | 2026-03-15T05:35:58.166900+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_791815 | REC_0005342 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 22 | 8.2 | 60 | female | 1 | 19 | 3 | 1 | osimertinib 80 mg daily | 18.9 | true | MSS | 2026-03-15T05:35:58.167132+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_154197 | REC_0005343 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 30 | 8.3 | 75 | female | 2 | 28 | 6 | 2 | carboplatin + paclitaxel + pembrolizumab | 10.3 | true | MSS | 2026-03-15T05:35:58.167361+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_813769 | REC_0005344 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 24 | 3.6 | 66 | female | 0 | 19 | 5.5 | 1 | carboplatin + paclitaxel + pembrolizumab | 16.4 | false | MSS | 2026-03-15T05:35:58.167637+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_136347 | REC_0005345 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 21 | 17.6 | 82 | female | 1 | 23 | 5.8 | 7 | pembrolizumab 200 mg q3w | 11.4 | false | MSS | 2026-03-15T05:35:58.167879+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_432959 | REC_0005346 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 5.8 | 69 | female | 0 | 68 | 6.7 | 7 | carboplatin + paclitaxel + pembrolizumab | 4 | false | MSS | 2026-03-15T05:35:58.168147+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_825333 | REC_0005347 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 30 | 11.6 | 61 | male | 0 | 23 | 6.8 | 1 | osimertinib 80 mg daily | 16 | false | MSS | 2026-03-15T05:35:58.168395+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_414446 | REC_0005348 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 23 | 14.5 | 65 | male | 1 | 19 | 4.3 | 2 | entrectinib 600 mg daily | 19.4 | false | MSS | 2026-03-15T05:35:58.168644+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_871310 | REC_0005349 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 5.4 | 71 | male | 1 | 34 | 6 | 7 | carboplatin + paclitaxel + pembrolizumab | 13.8 | true | MSS | 2026-03-15T05:35:58.168879+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_336762 | REC_0005350 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 9.1 | 68 | female | 0 | 13 | 4.2 | 4 | alectinib 600 mg BID | 8.9 | false | MSS | 2026-03-15T05:35:58.169107+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_606981 | REC_0005351 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 19 | 9.3 | 53 | male | 0 | 22 | 6 | 6 | alectinib 600 mg BID | 16.6 | false | MSS | 2026-03-15T05:35:58.169340+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_861132 | REC_0005352 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 12.9 | 74 | female | 1 | 14 | 4.5 | 8 | alectinib 600 mg BID | 7.9 | false | MSI-H | 2026-03-15T05:35:58.169569+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_387104 | REC_0005353 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 31 | 12.2 | 68 | female | 1 | 16 | 6.7 | 7 | sotorasib 960 mg daily | 10.8 | false | MSI-H | 2026-03-15T05:35:58.169803+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_666152 | REC_0005354 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 32 | 5.6 | 70 | female | 1 | 25 | 7.2 | 3 | osimertinib 80 mg daily | 8.2 | false | MSS | 2026-03-15T05:35:58.170034+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_840697 | REC_0005355 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 29 | 20.2 | 66 | female | 1 | 5 | 4.6 | 6 | alectinib 600 mg BID | 8.9 | true | MSS | 2026-03-15T05:35:58.170266+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_839746 | REC_0005356 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 20 | 12.6 | 80 | male | 2 | 26 | 6.5 | 2 | alectinib 600 mg BID | 17.2 | false | MSI-H | 2026-03-15T05:35:58.170500+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_476971 | REC_0005357 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 26 | 6.5 | 70 | female | 1 | 53 | 6.8 | 1 | pembrolizumab 200 mg q3w | 9.2 | false | MSS | 2026-03-15T05:35:58.170777+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_537364 | REC_0005358 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 25 | 12.2 | 64 | male | 0 | 29 | 4.5 | 2 | entrectinib 600 mg daily | 14.2 | true | MSI-H | 2026-03-15T05:35:58.171016+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_711561 | REC_0005359 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 32 | 13.4 | 76 | female | 2 | 13 | 4.1 | 2 | osimertinib 80 mg daily | 19.7 | false | MSS | 2026-03-15T05:35:58.171250+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_481042 | REC_0005360 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 11.5 | 77 | female | 2 | 7 | 4.9 | 3 | entrectinib 600 mg daily | 14.3 | true | MSI-H | 2026-03-15T05:35:58.171481+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_176506 | REC_0005361 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 25 | 8.7 | 73 | female | 2 | 13 | 6.9 | 1 | pembrolizumab 200 mg q3w | 13.1 | false | MSS | 2026-03-15T05:35:58.171715+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_446919 | REC_0005362 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 28 | 14.1 | 79 | male | 2 | 12 | 4.7 | 7 | sotorasib 960 mg daily | 11.8 | true | MSI-H | 2026-03-15T05:35:58.171953+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_833675 | REC_0005363 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 8.8 | 69 | female | 0 | 52 | 4 | 6 | carboplatin + paclitaxel + pembrolizumab | 9 | false | MSS | 2026-03-15T05:35:58.172219+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_312592 | REC_0005364 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 32 | 7.8 | 72 | male | 2 | 57 | 7.2 | 2 | carboplatin + paclitaxel + pembrolizumab | 13.9 | false | MSS | 2026-03-15T05:35:58.172455+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_329220 | REC_0005365 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 21 | 12.9 | 69 | female | 1 | 12 | 4.6 | 0 | sotorasib 960 mg daily | 67.1 | true | MSS | 2026-03-15T05:35:58.172692+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_372864 | REC_0005366 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 6.5 | 59 | male | 0 | 17 | 4 | 7 | sotorasib 960 mg daily | 16.1 | true | MSS | 2026-03-15T05:35:58.172926+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_548661 | REC_0005367 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 20 | 19.5 | 74 | female | 1 | 31 | 4.9 | 6 | alectinib 600 mg BID | 8.5 | true | MSS | 2026-03-15T05:35:58.173160+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_210817 | REC_0005368 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 23 | 7.1 | 72 | female | 2 | 71 | 6.8 | 1 | carboplatin + paclitaxel + pembrolizumab | 17.2 | false | MSS | 2026-03-15T05:35:58.173387+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_598776 | REC_0005369 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 32 | 13.6 | 82 | female | 0 | 13 | 4.9 | 6 | osimertinib 80 mg daily | 5.8 | true | MSS | 2026-03-15T05:35:58.173618+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_916081 | REC_0005370 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 29 | 17.2 | 67 | female | 1 | 12 | 5.7 | 6 | alectinib 600 mg BID | 13.8 | true | MSI-H | 2026-03-15T05:35:58.173896+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_837336 | REC_0005371 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 21 | 10.8 | 67 | female | 0 | 16 | 5.5 | 6 | osimertinib 80 mg daily | 8.6 | true | MSS | 2026-03-15T05:35:58.174132+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_327368 | REC_0005372 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 18 | 13.7 | 61 | female | 0 | 12 | 6.3 | 5 | osimertinib 80 mg daily | 12.1 | false | MSS | 2026-03-15T05:35:58.174367+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_181066 | REC_0005373 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 20 | 11.9 | 58 | male | 1 | 15 | 6.7 | 4 | alectinib 600 mg BID | 13.9 | false | MSS | 2026-03-15T05:35:58.174605+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_511030 | REC_0005374 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 24 | 13.8 | 71 | female | 1 | 19 | 5.5 | 1 | osimertinib 80 mg daily | 15.6 | false | MSI-H | 2026-03-15T05:35:58.174837+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_551553 | REC_0005375 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 20 | 18.9 | 78 | female | 2 | 11 | 3.1 | 5 | osimertinib 80 mg daily | 13.2 | true | MSI-H | 2026-03-15T05:35:58.175071+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_741187 | REC_0005376 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 25 | 9.2 | 70 | female | 1 | 26 | 6.1 | 1 | pembrolizumab 200 mg q3w | 11.1 | false | MSS | 2026-03-15T05:35:58.175297+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_155024 | REC_0005377 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 12.1 | 63 | male | 0 | 22 | 5.8 | 5 | osimertinib 80 mg daily | 9.8 | true | MSS | 2026-03-15T05:35:58.175532+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_639353 | REC_0005378 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 24 | 11.8 | 54 | male | 0 | 20 | 9.3 | 1 | entrectinib 600 mg daily | 22.2 | false | MSI-H | 2026-03-15T05:35:58.175765+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_350503 | REC_0005379 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 21 | 12.8 | 73 | female | 2 | 28 | 4.4 | 1 | osimertinib 80 mg daily | 14.5 | true | MSI-H | 2026-03-15T05:35:58.175996+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_751326 | REC_0005380 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 17 | 7.1 | 57 | male | 0 | 63 | 3.9 | 5 | pembrolizumab 200 mg q3w | 7.2 | true | MSS | 2026-03-15T05:35:58.176308+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_840710 | REC_0005381 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 21.5 | 75 | female | 1 | 14 | 5.7 | 5 | osimertinib 80 mg daily | 12.8 | true | MSI-H | 2026-03-15T05:35:58.176547+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_476956 | REC_0005382 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 22 | 10.1 | 66 | female | 0 | 17 | 5 | 2 | sotorasib 960 mg daily | 14 | true | MSS | 2026-03-15T05:35:58.176778+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_705590 | REC_0005383 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 29 | 8 | 72 | female | 2 | 17 | 4.6 | 0 | entrectinib 600 mg daily | 49.3 | true | MSS | 2026-03-15T05:35:58.177049+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_617128 | REC_0005384 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 14.2 | 54 | male | 0 | 13 | 3.7 | 4 | osimertinib 80 mg daily | 8.6 | false | MSS | 2026-03-15T05:35:58.177286+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_438369 | REC_0005385 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 11.1 | 69 | female | 0 | 19 | 5.3 | 4 | alectinib 600 mg BID | 12.7 | true | MSS | 2026-03-15T05:35:58.177518+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_817684 | REC_0005386 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 19 | 5.6 | 60 | male | 0 | 7 | 7.3 | 2 | sotorasib 960 mg daily | 4 | true | MSS | 2026-03-15T05:35:58.177750+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_790997 | REC_0005387 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 17 | 12.8 | 66 | female | 0 | 18 | 5.7 | 1 | osimertinib 80 mg daily | 23.3 | true | MSS | 2026-03-15T05:35:58.177985+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_728578 | REC_0005388 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 27 | 7.4 | 60 | male | 0 | 45 | 3.9 | 1 | carboplatin + paclitaxel + pembrolizumab | 8.5 | false | MSS | 2026-03-15T05:35:58.178215+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_594914 | REC_0005389 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 25 | 10.9 | 74 | female | 0 | 18 | 6 | 1 | osimertinib 80 mg daily | 17.9 | false | MSI-H | 2026-03-15T05:35:58.178448+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_443095 | REC_0005390 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 26 | 7.5 | 82 | male | 3 | 32 | 6.5 | 2 | carboplatin + paclitaxel + pembrolizumab | 29.3 | false | MSS | 2026-03-15T05:35:58.178678+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_667778 | REC_0005391 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 18.2 | 64 | male | 0 | 25 | 3.9 | 7 | entrectinib 600 mg daily | 9.3 | false | MSI-H | 2026-03-15T05:35:58.178917+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_234195 | REC_0005392 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 24 | 6.6 | 61 | male | 0 | 20 | 6.9 | 1 | carboplatin + paclitaxel + pembrolizumab | 26.2 | false | MSS | 2026-03-15T05:35:58.179149+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_334143 | REC_0005393 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 20 | 17.4 | 69 | male | 0 | 14 | 4.6 | 6 | osimertinib 80 mg daily | 10 | false | MSS | 2026-03-15T05:35:58.179386+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_181426 | REC_0005394 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 11.7 | 59 | male | 1 | 20 | 4.7 | 7 | osimertinib 80 mg daily | 11.2 | false | MSI-H | 2026-03-15T05:35:58.179623+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_364239 | REC_0005395 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 28 | 8.1 | 65 | female | 1 | 103 | 3.8 | 5 | carboplatin + paclitaxel + pembrolizumab | 11.6 | true | MSS | 2026-03-15T05:35:58.179854+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_129027 | REC_0005396 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 20 | 16.8 | 69 | female | 0 | 15 | 3.4 | 2 | osimertinib 80 mg daily | 23 | true | MSI-H | 2026-03-15T05:35:58.180188+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_965254 | REC_0005397 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 24 | 5 | 64 | male | 1 | 5 | 6.4 | 3 | pembrolizumab 200 mg q3w | 12.9 | true | MSS | 2026-03-15T05:35:58.180444+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_295953 | REC_0005398 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 18 | 13.9 | 71 | female | 1 | 12 | 4.7 | 2 | sotorasib 960 mg daily | 16.5 | true | MSS | 2026-03-15T05:35:58.180691+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_897844 | REC_0005399 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 29 | 6.8 | 58 | female | 0 | 43 | 5.8 | 0 | carboplatin + paclitaxel + pembrolizumab | 22.3 | true | MSS | 2026-03-15T05:35:58.180926+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_300857 | REC_0005400 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 14 | 12.5 | 65 | male | 1 | 22 | 7 | 2 | entrectinib 600 mg daily | 8.3 | false | MSI-H | 2026-03-15T05:35:58.181162+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.